

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/656,059
Filing Date	September 5, 2003
First Named Inventor	Hui Cai
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD0036NP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature	<i>Karl V. Jones</i>	Date Considered	<i>7/11/06</i>
-----------------------	----------------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**




INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 2

Application Number	10/656,059
Filing Date	September 5, 2003
First Named Inventor	Hui Cai
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD0036NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
M 2 ✓		DETTY, M.R. et al. Studies Toward Alkylthiophene-2-Carboxaldehydes. Reduction of 3-Alkenylthiophenes with Triethylsilane/Trifluoroacetic Acid. Regioselectivity in Formylation Reactions of 3-Alkylthiophenes. Heterocycles (1995) 40(2):925-937	1
		KONDO, K. et al. Synthetic Utility of tert-Butyl Azidoacetate on the Hemetsberger-Knittel Reaction (Synthetic Studies of Indoles and Related Compounds Part 47). Chem. Pharm. Bull. (1999) 47(8):1227-1231	
		IRIARTE, J. et al. The Chlorination of Thiophene-2-aldehyde and Ethyl Thiophene-2-carboxylate in the Presence of Excess Aluminum Chloride. J. Het. Chem. (1978) 13:393-394.	
		ARRANG, J.-M. et al. Auto-Inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor. Nature (1983) 302:832-837	
		ASH, A.S.F.; SCHILD, H.O. Receptors Mediating Some Actions of Histamine. Br. J. Pharmac. Chemother. (1968) 27:427-439	
		BARGER, G.; DALE, H.H. Chemical Structure and Sympathomimetic Action of Amines. J. Physiol. (1910) 41:19-59 Reprinted In Adventures in Physiology, Sir Henry H. Dale, Ed.; The Wellcome Trust: London, 1965; pp 67-88.	
		BLACK, J.W. et al. Definition and Antagonism of Histamine H2-Receptors. Nature (1972) 236:385-390	
		GANTZ, I. et al. Molecular Cloning of a Gene Encoding the Histamine H2 Receptor. Proc. Natl. Acad. Sci. USA (1991) 88:429-433	
		HILL, S.J. et al. International Union of Pharmacology. XIII. Classification of Histamine Receptors. Pharmacol. Rev. (1997) 49(3):253-278	
		LIU, C. et al. Cloning and Pharmacological Characterization of a Fourth Histamine Receptor (H4) Expressed in Bone Marrow. Mol. Pharmacol. (2001) 59(3):420-426	
		LOVENBERG, T.W. et al. Cloning and Functional Expression of the Human Histamine H3 Receptor. Mol. Pharmacol. (1999) 55(6):1101-1107	
		MORSE, K.L. et al. Cloning and Characterization of a Novel Human Histamine Receptor. J. Pharmacol. Exp. Ther. (2001) 296(3):1058-1066	
		NGUYEN, T. et al. Discovery of a Novel Member of the Histamine Receptor Family. Mol. Pharmacol. (2001) 59(3):427-433	
		ODA, T. et al. Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes. J. Biol. Chem. (2000) 275(47):36781-36788	
		RAIBLE, D.G. et al. Pharmacologic Characterization of a Novel Histamine Receptor on Human Eosinophils. Am. J. Respir. Crit. Care Med. (1994) 149:1508-1511	
	YAMASHITA, M. et al. Expression Cloning of a cDNA Encoding the Bovine Histamine H1 Receptor. Proc. Natl. Acad. Sci. USA (1991) 88:11515-11519		
	ZHU, Y. et al. Cloning, Expression, and Pharmacological Characterization of a Novel Human Histamine Receptor. Mol. Pharmacol. (2001) 59(3):434-441		

Examiner Signature		Date Considered	9/11/06
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Application Number	10/656,059
Filing Date	September 5, 2003
First Named Inventor	Hui Cai et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	PRD-36

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**